Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Noked Israel Ltd

Noked Israel Ltd increased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,285,359 shares of the company’s stock after acquiring an additional 418,006 shares during the quarter. Teva Pharmaceutical Industries comprises 14.3% of Noked Israel Ltd’s portfolio, making the stock its 3rd biggest holding. Noked Israel Ltd owned 0.29% of Teva Pharmaceutical Industries worth $72,409,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. FMR LLC increased its holdings in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Duquesne Family Office LLC raised its position in Teva Pharmaceutical Industries by 530.1% in the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock valued at $198,303,000 after purchasing an additional 7,569,450 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after buying an additional 4,418,961 shares during the period. Todd Asset Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $58,243,000. Finally, Marshall Wace LLP raised its holdings in Teva Pharmaceutical Industries by 87.8% during the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock worth $113,625,000 after purchasing an additional 2,410,420 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on TEVA shares. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, April 23rd. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $21.00 to $23.00 in a research report on Monday. Finally, UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $24.43.

Teva Pharmaceutical Industries Trading Down 2.7%

Shares of Teva Pharmaceutical Industries stock opened at $17.48 on Wednesday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a fifty day simple moving average of $15.22 and a 200 day simple moving average of $17.44. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a market capitalization of $19.82 billion, a P/E ratio of -12.06, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the prior year, the business posted $0.48 EPS. The business’s revenue was up 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.